Using CBPD-409 (ref. 26), a potent and orally bioavailable PROTAC designed to degrade both p300 and CBP, we achieve robust and selective suppression of enhancer-driven, AR-positive prostate cancer, surpassing the efficacy of conventional domain-specific inhibitors. The gene discussed is AR; the disease is prostate cancer.